Fig. 1

Impact of the DOCK11 deficiency in B cells on secondary immune responses. A, Experimental outline to examine secondary immune responses. B and D, Numbers of NP-specific IgG1⁺ antibody-secreting cells (ASCs) in the spleen from the indicated strains immunized with alum-precipitated NP-CGG, followed by boost immunization or not (PBS) with NP-CGG 28 d later, as measured by an ELISPOT assay 7 d after boost immunization. Each point represents an individual mouse. Bars represent geometric means. Data are pooled from three independent experiments, using four or more mice per experimental group. The values of anti-NP IgG1⁺ASC/10⁵ splenic cells ± SE in the control group and the experimental group in B are 2.0 ± 0.4 and 3.7 ± 1.4 (without immunization) and 43.2 ± 7.9 and 10.0 ± 2.6 (with immunization), respectively. The values of anti-NP IgG1⁺ASC/10⁵ splenic cells ± SE in the control group and the experimental group in D are 2.0 ± 0.3 and 3.0 ± 0.7 (without boosting) and 15.1 ± 2.6 and 25.0 ± 4.0 (with boosting), respectively. C and E, Concentrations of NP-specific IgG1 in the serum from the indicated strains 28 d post-immunization with alum-precipitated NP-CGG, followed by boost immunization with NP-CGG 7 d later, as measured by an ELISA. Each point represents an individual mouse. Bars represent geometric means. The numbers of mice in each group (B ~ E) are pooled from up to 4 independent experiments, using 4 ~ 8 mice per control group and 6 ~ 12 mice per experimental group. **P < 0.01, *P < 0.05 (Welch’s t-test)